WAILEA, Hawaii — Very few new adverse events related to the Port Delivery System device were seen in the 9 months following the primary endpoint of the Archway trial, according to a speaker here.
In 18-month follow-up data of the phase 3 trial of the PDS device (Genentech) with ranibizumab 100 mg/mL refilled every 24 weeks vs. ranibizumab 0.5 mg (Genentech) delivered intravitreally every 4 weeks, cataract was the most seen adverse event.
“Overall, up to 18 months, there is a slight imbalance: 8% in PDS; about 5% in intravitreal injections,” Carl D. Regillo, MD, said at Retina